Yongjie Ma

Yongjie Ma

Auto-generated profile, based on publicly available information

Yongjie Ma

Laboratory of Cancer Cell Biology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2025 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
PDF file
PSPusong Shi
Pusong Shi
YMYongjie Ma
Yongjie Ma
SZShaolu Zhang
Shaolu Zhang
Lactylation, a newly discovered protein posttranslational modification (PTM) in 2019, primarily occurs on lysine residues. Lactylation of histones was initially identified, and subsequent studies have increasingly demonstrated its widespread presence on non-histone proteins. Recently, high-throughput proteomics studies have identified a large number of lactylated proteins and sites, revealing their global regulatory role in disease development. Notably, this modification is catalyzed by lactyltransferase and reversed by delactylase, with numerous new enzymes, such as AARS1/2, reported to be involved. Specifically, these studies have revealed how lactylation exerts its influence through alterations in protein spatial conformation, molecular interactions, enzyme activity and subcellular localization. Indeed, lactylation is implicated in various physiological and pathological processes, including tumor development, cardiovascular and cerebrovascular diseases, immune cell activation and psychiatric disorders. This review provides the latest advancements in research on the regulatory roles of non-histone protein lactylation, highlighting its crucial scientific importance for future studies.

23 January 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
FQFengxia Qin
Fengxia Qin
HZHuikun Zhang
Huikun Zhang
YSYing Shao
Ying Shao
XLXiaoli Liu
Xiaoli Liu
LYLimin Yang
Limin Yang
YMYongjie Ma
Yongjie Ma
Expression of aquaporin1, a water channel protein, in cytoplasm is negatively correlated with prognosis of breast cancer patients

1 October 2019 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
BYBo Yang
Bo Yang
HDHaoqing Duan
Haoqing Duan
WCWenfeng Cao
Wenfeng Cao
YGYuhong Guo
Yuhong Guo
YLYanxue Liu
Yanxue Liu
YMYongjie Ma
Yongjie Ma

3 June 2019 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
YSYing Shao
Ying Shao
WCWei Chong
Wei Chong
XLXiaoli Liu
Xiaoli Liu
YXYun Xu
Yun Xu
HZHuikun Zhang
Huikun Zhang
FGFeng Gu
Feng Gu
Intersectin1 (ITSN1) contains two isoforms: ITSN1-S and ITSN1-L, which is highly regulated by alternative splicing. However, the alteration of alternative splicing and its importance in cancer is still unknown. In this study, our transcriptome analysis by using a large glioma cohort indicated the two isoforms exerted opposite function in glioma progression. Our previous results had shown ITSN1-S could promote glioma development; however, the function of ITSN1-L remained unknown. In this study, we first confirmed that ITSN1-L exerted an inhibitory role in glioma progression both in vivo and in vitro, which was contrary to the function of ITSN1-S. In additional, we also elucidated the mechanisms of ITSN1-L in inhibiting tumor progression. First, we revealed ITSN1-L could interact with α-tubulin to promote HDAC6-dependent deacetylation of ac-tubulin leading to decreased cell motility. Second, ITSN1-L could attenuate cell–substrate adhesion through FAK/integrin β3 pathway. Third, ITSN1-L was able to strengthen cell–cell adhesion by upregulating N-cadherin expression and its re-localization to membrane by ANXA2 and TUBB3/TUBB4. In conclusion, we found for the first time that two isoforms produced by alternative splicing exerted opposite functions in glioma development. Therefore, upregulation of ITSN1-L expression as well as downregulation of ITSN1-S expression probably was a better strategy in glioma treatment. Our present study laid a foundation for the importance of alternative splicing in glioma progression and raised the possibility of controlling glioma development completely at an alternative splicing level to be a more effective strategy.

19 August 2020 in Cell Death & Differentiation
Verified
Journal Article
Open access
PDF file
WCWei Chong
Wei Chong
HZHuikun Zhang
Huikun Zhang
ZGZhifang Guo
Zhifang Guo
LYLimin Yang
Limin Yang
YSYing Shao
Ying Shao
FGFeng Gu
Feng Gu
Anthracyclines are a class of conventional and commonly used frontline chemotherapy drugs to treat breast cancer. However, the anthracycline-based regimens can only reduce breast cancer mortality by 20–30%. Furthermore, there is no appropriate biomarker for predicting responses to this kind of chemotherapy currently. Here we report our findings that may fill this gap by showing the AQP1 (Aquaporin1) protein as a potential response predictor in the anthracycline chemotherapy. We showed that breast cancer patients with a high level of AQP1 expression who underwent the anthracycline treatment had a better clinical outcome relative to those with a low level of AQP1 expression. In the exploration of the underlying mechanisms, we found that the AQP1 and glycogen synthase kinase-3β (GSK3β) competitively interacted with the 12 armadillo repeats of β-catenin, followed by the inhibition of the β-catenin degradation that led to β-catenin’s accumulation in the cytoplasm and nuclear translocation. The nuclear β-catenin interacted with TopoIIα and enhanced TopoIIα’s activity, which resulted in a high sensitivity of breast cancer cells to anthracyclines. We also found, the miR-320a-3p can attenuate the anthracycline’s chemosensitivity by inhibiting the AQP1 expression. Taken together, our findings suggest the efficacy of AQP1 as a response predictor in the anthracycline chemotherapy. The application of our study includes, but is not limited to, facilitating screening of the most appropriate breast cancer patients (who have a high AQP1 expression) for better anthracycline chemotherapy and improved prognosis purposes.

12 August 2014 in Journal of Neurochemistry
Verified
Journal Article
Closed access
PDF file
FGFeng Gu
Feng Gu
LWLi Wang
Li Wang
JHJia He
Jia He
XLXiaoli Liu
Xiaoli Liu
HZHuikun Zhang
Huikun Zhang
YMYongjie Ma
Yongjie Ma